Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04285554Not ApplicableCompleted

Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

Role: lead

NCT04740723Not ApplicableCompleted

Evaluation of the Integrated Radio Frequency Denervation System for the Treatment of Hypertension

Role: lead

NCT04917393Not ApplicableUnknown

Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive

Role: lead

NCT02278068Not ApplicableCompleted

COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy

Role: lead

All 4 trials loaded